Efeito de um imunomodulador na qualidade do colostro e na incidência de doenças no pós-parto de vacas leiteiras

Dissertação de Mestrado Integrado em Medicina VeterináriaEste estudo analisou a eficácia do pegbovigrastim (ImrestorTM) na incidência de doenças no pós-parto de vacas leiteiras e o seu efeito na qualidade do colostro. Às vacas do grupo experimental foi administrado pegbovigrastim e às vacas do grupo controlo soro fisiológico. Não se observaram diferenças significativas no número de neutrófilos e macrófagos nos esfregaços de colostro. Contudo, os seus valores máximos foram superiores no colostro de vacas do grupo ImrestorTM. Verificou-se que no colostro não centrifugado das vacas tratadas com ImrestorTM o número de linfócitos foi tendencialmente superior (p=0,08). O colostro de vacas que receberam as duas doses de ImrestorTM teve uma média de 300 mil células/ml superior ao colostro do grupo controlo. A incidência de mastites, metrites e RP foi inferior no grupo experimental, comparativamente ao grupo controlo, contudo esta redução não foi estatisticamente significativa. O valor Brix foi semelhante entre os dois grupos em estudo. Não se observaram diferenças significativas entre os dois grupos na produção leiteira acumulada no primeiro mês após o parto. A percentagem de vacas com hipercetonémia foi 5,3% no grupo experimental e 8,2% no grupo controlo. É de todo o interesse que futuramente se desenvolvam mais estudos de modo a obter conclusões mais consolidadas.ABSTRACT - EFFECT OF AN IMMUNOMODULATOR IN THE QUALITY OF COLOSTRUM AND THE INCIDENCE OF DISEASES IN THE POSTPARTUM OF DAIRY COWS - This study examined the efficacy of pegbovigrastim (ImrestorTM) on the incidence of postpartum diseases in dairy cows and its effect on the quality of colostrum. Cows in the experimental group received pegbovigrastim and cows in the control group saline solution. No significant differences were observed in the number of neutrophils and macrophages in the colostrum. However, its maximum values were higher in colostrum of the ImrestorTM group. It was found that in the non-centrifuged colostrum of cows treated with ImrestorTM the number of lymphocytes was tendentially higher (p=0,08). The colostrum of cows that received the two doses of ImrestorTM was an average of 300,000 cells/ml higher than colostrum in the control group. The incidence of mastitis, metritis and RP was lower in the experimental group, compared to the control group, but this reduction was not statistically significant. The Brix value was similar between the two groups under study. There were no significant differences between the two groups in milk production accumulated in the first month after calving. The percentage of cows with hyperketonemia was 5.3% in the experimental group and 8.2% in the control group. It is of great interest that more studies are carried out in the future in order to obtain more consolidated conclusions.Fonte de Leite Exploração Agrícola e Pecuária, S.A.N/

Serotonin Deficiency Increases Context-Dependent Fear Learning Through Modulation of Hippocampal Activity

Brain serotonin (5-hydroxytryptamine, 5-HT) system dysfunction is implicated in exaggerated fear responses triggering various anxiety-, stress-, and trauma-related disorders. However, the underlying mechanisms are not well understood. Here, we investigated the impact of constitutively inactivated 5-HT synthesis on context-dependent fear learning and extinction using tryptophan hydroxylase 2 ( ) knockout mice. Fear conditioning and context-dependent fear memory extinction paradigms were combined with c-Fos imaging and electrophysiological recordings in the dorsal hippocampus (dHip). mutant mice, completely devoid of 5-HT synthesis in brain, displayed accelerated fear memory formation and increased locomotor responses to foot shock. Furthermore, recall of context-dependent fear memory was increased. The behavioral responses were associated with increased c-Fos expression in the dHip and resistance to foot shock-induced impairment of hippocampal long-term potentiation (LTP). In conclusion, increased context-dependent fear memory resulting from brain 5-HT deficiency involves dysfunction of the hippocampal circuitry controlling contextual representation of fear-related behavioral responses.</p

Serotonin Deficiency Increases Context-Dependent Fear Learning Through Modulation of Hippocampal Activity

Brain serotonin (5-hydroxytryptamine, 5-HT) system dysfunction is implicated in exaggerated fear responses triggering various anxiety-, stress-, and trauma-related disorders. However, the underlying mechanisms are not well understood. Here, we investigated the impact of constitutively inactivated 5-HT synthesis on context-dependent fear learning and extinction using tryptophan hydroxylase 2 (Tph2) knockout mice. Fear conditioning and context-dependent fear memory extinction paradigms were combined with c-Fos imaging and electrophysiological recordings in the dorsal hippocampus (dHip). Tph2 mutant mice, completely devoid of 5-HT synthesis in brain, displayed accelerated fear memory formation and increased locomotor responses to foot shock. Furthermore, recall of context-dependent fear memory was increased. The behavioral responses were associated with increased c-Fos expression in the dHip and resistance to foot shock-induced impairment of hippocampal long-term potentiation (LTP). In conclusion, increased context-dependent fear memory resulting from brain 5-HT deficiency involves dysfunction of the hippocampal circuitry controlling contextual representation of fear-related behavioral responses

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Die Effekte einer Serotonindefizienz in der Maus: Das GABAerge System im Blickpunkt

Based on genetic association and functional imaging studies, reduced function of tryptophan hydroxylase-2 (TPH2) has been shown to be critically involved in the pathophysiology of anxiety-disorders and depression. In order to elucidate the impact of a complete neuronal 5-HT deficiency, mice with a targeted inactivation of the gene encoding Tph2 were generated. Interestingly, survival of Tph2-/- mice, the formation of serotonergic neurons and the pathfinding of their projections was not impaired. Within this thesis, I investigated the influence of 5-HT deficiency on the γ-amino butyric acid (GABA) system. The GABAergic system is implicated in the pathophysiology of anxiety disorders. Therefore, measurement of GABA concentrations in different limbic brain regions was carried out. These measurements were combined with immunohistochemical estimation of GABAergic cell subpopulations in the dorsal hippocampus and amygdala. In Tph2-/- mice GABA concentrations were increased exclusively in the dorsal hippocampus. In heterozygous Tph2+/- mice concentrations of GABA were increased in the amygdala compared to Tph2-/- and wt control mice, while the reverse was found in the prefrontal cortex. The changes in GABA concentrations were accompanied by altered cell density of GABAergic neurons within the basolateral complex of the amygdala and parvalbumin (PV) neurons of the dorsal hippocampus and by adaptational changes of 5-HT receptors. Thus, adaptive changes during the development on the GABA system may reflect altered anxiety-like and depressive-like behavior in adulthood. Moreover, chronic mild stress (CMS) rescues the depressive-like effects induced by 5-HT deficiency. In contrast, 5-HT is important in mediating an increased innate anxiety-like behavior under CMS conditions. This is in line with a proposed dual role of 5-HT acting through different mechanisms on anxiety and depressive-like behavior, which is influenced by gene-environment interaction effects. Further research is needed to disentangle these complex networks in the future.Genomweite Assoziationsstudien in Kombination mit bildgebenden Studien zeigten, dass eine verringerte Funktion der Tryptophanhydroxylase-2 (Tph2) eine zentrale Rolle in der Pathophysiologie von Angststörungen und Depression spielt. Jedoch sind die einer Angststörung oder Depression zugrundeliegenden genauen Mechanismen noch nicht verstanden. Um den Einfluss einer 5-HT Defizienz zu untersuchen, wurden Tph2 ablatierte (Tph2-/-) Mäuse mittels zielgerichteter Mutagenese generiert. Der Verlust des Tph2 Gens hatte interessanterweise keinen Einfluss auf die Entwicklung vormals serotonerger Neurone und das Überleben der Tiere. In vorherigen Untersuchungen konnte gezeigt werden, dass 5-HT das GABAerge System, welches in der Pathophysiologie von Angststörungen eine zentrale Rolle spielt, in seiner Entwicklung beeinflusst. Daher wurden im Rahmen dieser Arbeit in verschiedenen Gehirnregionen des limbischen Systems Konzentrationen von GABA gemessen. Außerdem wurden mittels immunhistologischer Untersuchungen die Auswirkungen einer 5-HT Defizienz auf GABAerge Neuronenpopulationen hin untersucht. In Tph2-/- Mäusen wurden erhöhte Konzentrationen im Vergleich zu Tph2+/- und wt Kontrollen von GABA im Hippocampus festgestellt. In der Amygdala zeigten die Tph2+/- Mäuse dagegen eine erhöhte Konzentration von GABA. Dieser Effekt auf Tph2+/- Mäuse war umgekehrt im PFC Kortex zu finden, der erniedrigte GABA Konzentrationen in Tph2+/- aufwies. Die Veränderungen auf der neurochemischen Ebene wurden begleitet von veränderten GABAergen Zelldichten im basolateralen Komplex der Amygdala und parvalbuminergen GABAergen Neuronen in der CA3 Region des dorsalen hippocampus. Zudem waren 5-HT1A Rezeptoren und ihre Signalwege hochreguliert. Es scheint, dass der Verlust von 5-HT adaptive Veränderungen in der Entwicklung auf das GABAerge System zur Folge hat und die Basis für verändertes angstähnliches und depressionsähnliches Verhalten im Erwachsenenalter darstellt. Zusätzlich scheint eine 5-HT Defizienz den depressiven Phänotyp im Porsolt Test auszugleichen. Demgegenüber scheint 5-HT wichtig für ein erhöhtes angstähnliches Verhalten unter CMS Bedingungen zu sein. Dies unterstützt die Hypothese einer Doppelrolle von 5-HT innerhalb von Signalwegen und Mechanismen des angst- und depressionsähnlichem Verhalten, die durch Umweltfaktoren wie Stress stark beeinflusst werden. Um den Patienten noch besser helfen zu können erfordert dies in der Zukunft weiterhin eine fundierte Entschlüsselung der dahinter verborgenen Mechanismen

Serotonin in the Modulation of Neural Plasticity and Networks: Implications for Neurodevelopmental Disorders

Serotonin (5-HT) shapes brain networks during development and modulates a wide spectrum of essential neuronal functions ranging from perception and cognitive appraisal to emotional responses in the mature brain. Deficits in 5-HT-moderated synaptic signaling fundamentally impact the pathophysiology and long-term outcome of neurodevelopmental disorders. Our understanding of how 5-HT-dependent modulation of circuit configuration influences social cognition and emotional learning has been enhanced by recent insight into the molecular and cellular mechanisms of synapse formation and plasticity. In this review, we discuss emerging concepts as to how defects in synaptic plasticity impact our biosocial brain and how recent findings regarding 5-HT’s role in brain development and function provide insight into the cellular and physiological basis of neurodevelopmental disorders